Friday, 20 January 2017

The Conventional Medicine: Treatment of Dementia associated to Creutzfeldt-Jakob disease - Quinacrine

Kyle J. Norton (Scholar) 
Health article writer and researcher; Over 10.000 articles and research papers have been written and published on line, including world wide health, ezine articles, article base, healthblogs, selfgrowth, best before it's news, the karate GB daily, etc.,.
Named TOP 50 MEDICAL ESSAYS FOR ARTISTS & AUTHORS TO READ by Disilgold.com Named 50 of the best health Tweeters Canada - Huffington Post
Nominated for shorty award over last 4 years
Some articles have been used as references in medical research, such as international journal Pharma and Bio science, ISSN 0975-6299.


                                 Dementia

Dementia is defined as neuro degeneration syndrome among elder, affecting memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgement over 47 millions
of worldwide population, mostly in the West. The evaluation of the syndrome by holistic medicine has been lacking, especially through conventional medicine research and studies.



     Treatment of Dementia associated to Creutzfeldt-Jakob disease -  Quinacrine


People who have eaten contaminated beef in a prolonged period of times may be infected by infectious agent prion(514) without even knowing it. Creutzfeldt-Jakob disease is a quickly progressing and fatal disease(513) inducing dementia(515), especially in elder(516), causing degeneration of skeletal muscle, peripheral nerves(517) linked to mutations in the PrP gene(518). CJD is characterized by rapidly progressive dementia(513)(519). Initially, individuals experience of epilepsy seizure(519), problems with muscular coordination(522); cognitive change (loss of motor planning, loss of motor functioning's, inability to speak)(519), such as impaired memory(521), loss of functional independence(523) and impaired vision(520). People with the disease also may experience insomnia(524)(525), depression(526)(527), or unusual sensations(522).


a. Quinacrine used for treatment of giardiasis caused by Giardia lamblia(535) may be a potential medicine for treatment of Creutzfeldt-Jakob disease(CJD)(536)(537), according to a report in The Mail on Sunday 12 August 2001, entitled "Briton 'cured' in CJD drug trial"(534).
Although Quinacrine at a dose of 300 mg per day was reasonably tolerated, it did not induce significantly affect in course of prion diseases(537), including Creutzfeldt-Jakob disease (CJD(538)(539).
b. Most common side effects are not limit to
b.1. Abdominal and cramps
b.2. Diarrhea
b.3. Fever
b.4. Headache
b.5. loss of appetite
b.6. Changes in menstrual flow
b.7. Nausea and vomiting

(513) Human prion diseases: from Kuru to variant Creutzfeldt-Jakob disease by Sikorska B1, Liberski PP.(PubMed)
(514) An overview of human prion diseases by Imran M1, Mahmood S.(PubMed)
(515) Rapidly progressive dementia: prion diseases and other rapid dementias by Geschwind MD.(PubMed)
(516) Neuroimaging of rapidly progressive dementias, part 1: neurodegenerative etiologies by Degnan AJ1, Levy LM.(PubMed)
(517) Degeneration of skeletal muscle, peripheral nerves, and the central nervous system in transgenic mice overexpressing wild-type prion proteins by Westaway D1, DeArmond SJ, Cayetano-Canlas J, Groth D, Foster D, Yang SL, Torchia M, Carlson GA, Prusiner SB.(PubMed)
(518) Prion protein transgenes and the neuropathology in prion diseases by DeArmond SJ1, Prusiner SB.(PubMed)
(519) [Differential diagnosis of status epilepticus in intensive care: about one case of sporadic Creutzfeldt-Jakob].[Article in French] by Chauvin A1, Dubost JL2, Cleophax C2, Niclot P3, Thuong M2.(PubMed)
(520) Prion protein accumulation in eyes of patients with sporadic and variant Creutzfeldt-Jakob disease by Head MW1, Northcott V, Rennison K, Ritchie D, McCardle L, Bunn TJ, McLennan NF, Ironside JW, Tullo AB, Bonshek RE.(PubMed)
(521) Fast progressive memory loss in a 63-year-old man by De Smet K1, De Maeseneer M, Amir TY, De Mey J.(PubMed)
(522) Creutzfeldt-Jakob Disease Fact Sheet(NIH)
(523) Accuracy of diagnostic criteria for sporadic creutzfeldt-jakob disease among rapidly progressive dementia by Tagliapietra M1, Zanusso G, Fiorini M, Bonetto N, Zarantonello G, Zambon A, Ermani M, Monaco S, Manara R, Cagnin A.(PubMed)
(524) Hereditary Creutzfeldt-Jakob disease and fatal familial insomnia by Gambetti P1, Parchi P, Chen SG.(PubMed)
(525) Genetic Creutzfeldt-Jakob disease and fatal familial insomnia: insights into phenotypic variability and disease pathogenesis. by Capellari S1, Strammiello R, Saverioni D, Kretzschmar H, Parchi P.;(PubMed)
(526) Sporadic Creutzfeldt-Jakob disease presenting as major depression by Jiang TT1, Moses H, Gordon H, Obah E.(PubMed)
(527) [Course of anxiety, depression, and quality of life in relatives of patients with Creutzfeldt-Jakob-Disease][Article in German]by Riedemann C1, Zerr I, Kropp S, Otto A, Poser S, Herrmann C.(PubMed)

Thursday, 19 January 2017

The Conventional Medicine: Treatment of Dementia associated to Creutzfeldt-Jakob disease - Interleukins

Kyle J. Norton (Scholar) 
Health article writer and researcher; Over 10.000 articles and research papers have been written and published on line, including world wide health, ezine articles, article base, healthblogs, selfgrowth, best before it's news, the karate GB daily, etc.,.
Named TOP 50 MEDICAL ESSAYS FOR ARTISTS & AUTHORS TO READ by Disilgold.com Named 50 of the best health Tweeters Canada - Huffington Post
Nominated for shorty award over last 4 years
Some articles have been used as references in medical research, such as international journal Pharma and Bio science, ISSN 0975-6299.


                                 Dementia

Dementia is defined as neuro degeneration syndrome among elder, affecting memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgement over 47 millions
of worldwide population, mostly in the West. The evaluation of the syndrome by holistic medicine has been lacking, especially through conventional medicine research and studies.



     Treatment of Dementia associated to Creutzfeldt-Jakob disease - Interleukins


People who have eaten contaminated beef in a prolonged period of times may be infected by infectious agent prion(514) without even knowing it. Creutzfeldt-Jakob disease is a quickly progressing and fatal disease(513) inducing dementia(515), especially in elder(516), causing degeneration of skeletal muscle, peripheral nerves(517) linked to mutations in the PrP gene(518). CJD is characterized by rapidly progressive dementia(513)(519). Initially, individuals experience of epilepsy seizure(519), problems with muscular coordination(522); cognitive change (loss of motor planning, loss of motor functioning's, inability to speak)(519), such as impaired memory(521), loss of functional independence(523) and impaired vision(520). People with the disease also may experience insomnia(524)(525), depression(526)(527), or unusual sensations(522).

There is no treatment that can cure or control CJD. The available treatments are to relieve the symptoms and may help slow the disease.
1. Interleukins
a. Interleukins is defined as any group of naturally occurring proteins that mediate communication between cells(528), produced by while blood cells. The set of interleukins stimulated by a specific infectious agent in determined cells in responding to the infection and influences(528) through its modulated inflammation and immune response.(529).
According to University Hospital Göttingen, interleukin 10 levels, inflammatory cytokines(530) were significantly elevated in the cerebrospinal fluid of CJD, dementia, motoneuron disease patients through it inflammatory cytokines(529). Cyclooxygenase-2 (COX-2)(532) and prostaglandins (PGs)(533) are the most conventional medicine used to treat neurotoxiticy in acute conditions, including in inflammatory chronic diseases, such as Creutzfeldt-Jakob disease (CJD) and Alzheimer's disease (AD)(531).

b. Common side effects are not limit to
b.1. Cyclooxygenase-2 (COX-2)
b.1.1 Insomnia,
b.1.2 Abdominal pain,
b.1.3. Flatulence (gas),
b.1.4. Headache ,
b.1.5. Nausea and diarrhea.

b.2. Prostaglandins (PGs)
b.2. Dizziness
b.2.2. Fainting
b.2.3. Irregular heartbeat or pulse•
b.2.4. Slow heartbeat
(513) Human prion diseases: from Kuru to variant Creutzfeldt-Jakob disease by Sikorska B1, Liberski PP.(PubMed)
(514) An overview of human prion diseases by Imran M1, Mahmood S.(PubMed)
(515) Rapidly progressive dementia: prion diseases and other rapid dementias by Geschwind MD.(PubMed)
(516) Neuroimaging of rapidly progressive dementias, part 1: neurodegenerative etiologies by Degnan AJ1, Levy LM.(PubMed)
(517) Degeneration of skeletal muscle, peripheral nerves, and the central nervous system in transgenic mice overexpressing wild-type prion proteins by Westaway D1, DeArmond SJ, Cayetano-Canlas J, Groth D, Foster D, Yang SL, Torchia M, Carlson GA, Prusiner SB.(PubMed)
(518) Prion protein transgenes and the neuropathology in prion diseases by DeArmond SJ1, Prusiner SB.(PubMed)
(519) [Differential diagnosis of status epilepticus in intensive care: about one case of sporadic Creutzfeldt-Jakob].[Article in French] by Chauvin A1, Dubost JL2, Cleophax C2, Niclot P3, Thuong M2.(PubMed)
(520) Prion protein accumulation in eyes of patients with sporadic and variant Creutzfeldt-Jakob disease by Head MW1, Northcott V, Rennison K, Ritchie D, McCardle L, Bunn TJ, McLennan NF, Ironside JW, Tullo AB, Bonshek RE.(PubMed)
(521) Fast progressive memory loss in a 63-year-old man by De Smet K1, De Maeseneer M, Amir TY, De Mey J.(PubMed)
(522) Creutzfeldt-Jakob Disease Fact Sheet(NIH)
(523) Accuracy of diagnostic criteria for sporadic creutzfeldt-jakob disease among rapidly progressive dementia by Tagliapietra M1, Zanusso G, Fiorini M, Bonetto N, Zarantonello G, Zambon A, Ermani M, Monaco S, Manara R, Cagnin A.(PubMed)
(524) Hereditary Creutzfeldt-Jakob disease and fatal familial insomnia by Gambetti P1, Parchi P, Chen SG.(PubMed)
(525) Genetic Creutzfeldt-Jakob disease and fatal familial insomnia: insights into phenotypic variability and disease pathogenesis. by Capellari S1, Strammiello R, Saverioni D, Kretzschmar H, Parchi P.;(PubMed)
(526) Sporadic Creutzfeldt-Jakob disease presenting as major depression by Jiang TT1, Moses H, Gordon H, Obah E.(PubMed)
(527) [Course of anxiety, depression, and quality of life in relatives of patients with Creutzfeldt-Jakob-Disease][Article in German]by Riedemann C1, Zerr I, Kropp S, Otto A, Poser S, Herrmann C.(PubMed)


(528) Interleukin (IL) Protein Written by: The Editors of Encyclopædia Britannica
(529) Interleukin 4 and interleukin 10 levels are elevated in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease by Stoeck K1, Bodemer M, Ciesielczyk B, Meissner B, Bartl M, Heinemann U, Zerr I.(PubMed)
(530) The role of inflammatory cytokines as key modulators of neurogenesis by Borsini A1, Zunszain PA1, Thuret S2, Pariante CM3.(PubMed)

(531) Role of COX-2 in inflammatory and degenerative brain diseases. by Minghetti L1(PubMed)
(532) Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases by Minghetti L1.(PubMed)
(533) Prostaglandins and cyclooxygenases in glial cells during brain inflammation by Tzeng SF1, Hsiao HY, Mak OT.(PubMed)

Wednesday, 18 January 2017

The Conventional Treatment of Dementia associated with Parkinson's disease Side Effects

Kyle J. Norton (Scholar) 
Health article writer and researcher; Over 10.000 articles and research papers have been written and published on line, including world wide health, ezine articles, article base, healthblogs, selfgrowth, best before it's news, the karate GB daily, etc.,.
Named TOP 50 MEDICAL ESSAYS FOR ARTISTS & AUTHORS TO READ by Disilgold.com Named 50 of the best health Tweeters Canada - Huffington Post
Nominated for shorty award over last 4 years
Some articles have been used as references in medical research, such as international journal Pharma and Bio science, ISSN 0975-6299.


                                 Dementia

Dementia is defined as neuro degeneration syndrome among elder, affecting memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgement over 47 millions
of worldwide population, mostly in the West. The evaluation of the syndrome by holistic medicine has been lacking, especially through conventional medicine research and studies.



     Treatment of Dementia associated with Parkinson's disease side effects


Parkinson disease (PD) is a disabling, progressive condition induced symptoms of olfactory deficit, sleep problems such as rapid eye movement behaviour disorder, constipation and the more recently described male erectile dysfunction(456), due to the interruption of frontal-subcortical loops facilitated cognition and parallel the motor loop(457).
Contrary to common perception, many non-motor symptoms (NMS) also link to early onset of PD(459) and some may even predate the diagnosis of PD based on motor signs(458).

Most conventional medicine induced certain side effects. If you are taken any of these medicine, please consult your doctor. You also can search them from respectable sources. Here are some examples.
a, Macrogol(Allergic reaction (rash, itching, shortness of breath) changes in your body's fluid or electrolyte levels (swollenankles, other swelling, fatigue, dehydration, increased thirst with headache), Abdominal pain. Mild diarrhoea. Nausea. Vomiting. Swollen abdomen)(510).
b. Methylphenidate (stomach pain, nausea, vomiting, loss of appetite; vision problems, dizziness, mild headache; sweating, mild skin rash; numbness, tingling, or cold feeling in your hands or feet; nervous feeling, sleep problems (insomnia); or. weight loss)(511).
c. Modafinil (Black, tarry stools, blurred vision or other vision changes, chest pain, chills or fever, clumsiness or unsteadiness, confusion, dizziness or fainting, increased thirst and urination, mental depression, problems with memory, rapidly changing moods, shortness of breath, sore throat, trembling or shaking, trouble in urinating, uncontrolled movements of the face, mouth, or tongue unusual bleeding or bruising and unusual tiredness or weakness)(512).
d. Etc.

((457) Frontal-subcortical circuitry and behavior by Bonelli RM1, Cummings JL.(PubMed)
(458) Non-motor symptoms of Parkinson's disease: diagnosis and management by Salawu FK1, Danburam A, Olokoba AB.(PubMed)
(459) Early Parkinson's disease and non-motor issues by Chaudhuri KR1, Naidu Y.(PubMed)
(510) Medicines & treatments centre(WebMD)
(511) Ritalin Side Effects Center(WebMD)
(512) Modafinil Side Effects(Drug.com)

Tuesday, 17 January 2017

The Conventional Treatment of Dementia associated for the motor symptoms of Parkinson's disease

Kyle J. Norton (Scholar) 
Health article writer and researcher; Over 10.000 articles and research papers have been written and published on line, including world wide health, ezine articles, article base, healthblogs, selfgrowth, best before it's news, the karate GB daily, etc.,.
Named TOP 50 MEDICAL ESSAYS FOR ARTISTS & AUTHORS TO READ by Disilgold.com Named 50 of the best health Tweeters Canada - Huffington Post
Nominated for shorty award over last 4 years
Some articles have been used as references in medical research, such as international journal Pharma and Bio science, ISSN 0975-6299.


                                 Dementia

Dementia is defined as neuro degeneration syndrome among elder, affecting memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgement over 47 millions
of worldwide population, mostly in the West. The evaluation of the syndrome by holistic medicine has been lacking, especially through conventional medicine research and studies.



     Treatment of Dementia associated for the motor symptoms of Parkinson's disease


Parkinson disease (PD) is a disabling, progressive condition induced symptoms of olfactory deficit, sleep problems such as rapid eye movement behaviour disorder, constipation and the more recently described male erectile dysfunction(456), due to the interruption of frontal-subcortical loops facilitated cognition and parallel the motor loop(457).
Contrary to common perception, many non-motor symptoms (NMS) also link to early onset of PD(459) and some may even predate the diagnosis of PD based on motor signs(458).

According to the Movement Disorder Society (MDS) Task Force on Evidence-Based Medicine (EBM) Review of Treatments for Parkinson's Disease (PD) was first published in 2002 and updated in 2005 to cover clinical trial data up to January 2004 with the treatments on motor symptoms of PD(489), including

a. Piribedil(490)(491), pramipexole(491), pramipexole extended release(492)(493), ropinirole(491), rotigotine(494), cabergoline(491), and pergolide(491) were all efficacious as symptomatic monotherapy
b. Ropinirole prolonged release(495) was likely efficacious as a symptomatic adjunct therapy
c. Prevention/delay of motor fluctuations, pramipexole(496) and cabergoline(497) were efficacious
d. Prevention/delay of dyskinesia, pramipexole(498), ropinirole(499), ropinirole prolonged release(500), and cabergoline(501) were all efficacious, whereas pergolide(502) was likely efficacious.
e. Duodenal infusion of levodopa(502)(503) was likely efficacious in the treatment of motor complications, but the practice implication is investigational.
f. Rasagiline conclusions were revised to efficacious as a symptomatic adjunct(504), and as treatment for motor fluctuations(505).
g. Bilateral subthalamic nucleus deep brain stimulation(506), bilateral globus pallidus stimulation(507), and unilateral pallidotomy(508) were updated to efficacious for motor complications.
h. Physical therapy(509)was revised to likely efficacious as symptomatic adjunct therapy.

((457) Frontal-subcortical circuitry and behavior by Bonelli RM1, Cummings JL.(PubMed)
(458) Non-motor symptoms of Parkinson's disease: diagnosis and management by Salawu FK1, Danburam A, Olokoba AB.(PubMed)
(459) Early Parkinson's disease and non-motor issues by Chaudhuri KR1, Naidu Y.(PubMed)
(488) Practice Parameter: Treatment of nonmotor symptoms of Parkinson disease
Report of the Quality Standards Subcommittee of the American Academy of Neurology by T. A.Zesiewicz, MD, FAAN, K. L. Sullivan, MSPH, I. Arnulf, MD, K. R. Chaudhuri, MD, J. C.Morgan, MD, PhD, G. S. Gronseth, MD, FAAN, J. Miyasaki, MD, MEd, FAAN, D. J. Iverson, MD, FAAN and W. J. Weiner, MD(Neurology)
(489) The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease by Fox SH1, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, Poewe W, Rascol O, Goetz CG, Sampaio C.(PubMed)
(490) Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset by Smith LA1, Jackson MG, Bonhomme C, Chezaubernard C, Pearce RK, Jenner P.(PubMed)
(491) Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease by Deleu D1, Northway MG, Hanssens Y.(PubMed)
(492) Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease by Hametner EM1, Seppi K, Poewe W.(PubMed)
(493) Pramipexole extended-release: a review of its use in patients with Parkinson's disease by Frampton JE1.(PubMed)
(494) Role of dopamine receptor agonists in the treatment of early Parkinson's disease. by Bonuccelli U1, Del Dotto P, Rascol O.(PubMed).
(495) Long-term, open-label, safety study of once-daily ropinirole extended/prolonged release in early and advanced Parkinson's disease by Makumi CW1, Asgharian A, Ellis J, Shaikh S, Jimenez T, VanMeter S.(PubMed)
(496) Pramipexole and its extended release formulation for Parkinson's disease by Fishman PS1.(PubMed)
(497) [Dopamine agonists in the treatment of motor complications in advanced Parkinson's disease].[Article in Polish] by Sławek J1.(PubMed)
(498) Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease by Hauser RA, Schapira AH, Barone P, Mizuno Y, Rascol O, Busse M, Debieuvre C, Fraessdorf M, Poewe W; Pramipexole ER Studies Group.(PubMed)
(499) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa by Rascol O1, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE.(PubMed)
(500) Economic evaluation of ropinirole prolonged release for treatment of Parkinson's disease in the Netherlands by van Boven JF1, Novak A, Driessen MT, Boersma C, Boomsma MM, Postma MJ.(PubMed)
(501) Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients by Perez-Lloret S1, Rey MV, Crispo J, Krewski D, Lapeyre-Mestre M, Montastruc JL, Rascol O.(PubMed)
(502) Interaction of pergolide with central dopaminergic receptors. by Goldstein M, Lieberman A, Lew JY, Asano T, Rosenfeld MR, Makman MH.(PubMed)
(503) Medical management of levodopa-associated motor complications in patients with Parkinson's disease by Jankovic J1, Stacy M.(PubMed)
(504) [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].[Article in Spanish] by Pagonabarraga J1, Rodríguez-Oroz MC.(PubMed)
(505) Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease. by McCormack PL1.(PubMed)
(506) Subthalamic nucleus deep brain stimulation for Parkinson's disease: evidence for effectiveness and limitations from 12 years' experience. by Movement Disorder Group, Chan AY1, Yeung JH2, Mok VC1, Ip VH1, Wong A1, Kuo SH3, Chan DT4, Zhu XL4, Wong E4, Lau CK4, Wong RK5, Tang V6, Lau C1,Poon WS4.(PubMed)
(507) Deep brain stimulation for the treatment of Parkinson's disease: subthalamic nucleus versus globus pallidus internus by Krause M1, Fogel W, Heck A, Hacke W, Bonsanto M, Trenkwalder C, Tronnier V.(PubMed)
(508) Bilateral pallidotomy for treatment of Parkinson's disease induced corticobulbar syndrome and psychic akinesia avoidable by globus pallidus lesion combined with contralateral stimulation by Merello M1, Starkstein S, Nouzeilles MI, Kuzis G, Leiguarda R.(PubMed)
(509) Maintenance ECT in the treatment of PD. Therapy improves psychotic symptoms, physical function by Shulman RB1.(PubMed)

Monday, 16 January 2017

The Conventional Treatment of Dementia associated with Parkinson's disease

Kyle J. Norton (Scholar) 
Health article writer and researcher; Over 10.000 articles and research papers have been written and published on line, including world wide health, ezine articles, article base, healthblogs, selfgrowth, best before it's news, the karate GB daily, etc.,.
Named TOP 50 MEDICAL ESSAYS FOR ARTISTS & AUTHORS TO READ by Disilgold.com Named 50 of the best health Tweeters Canada - Huffington Post
Nominated for shorty award over last 4 years
Some articles have been used as references in medical research, such as international journal Pharma and Bio science, ISSN 0975-6299.


                                 Dementia

Dementia is defined as neuro degeneration syndrome among elder, affecting memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgement over 47 millions
of worldwide population, mostly in the West. The evaluation of the syndrome by holistic medicine has been lacking, especially through conventional medicine research and studies.



     Treatment of Dementia associated with Parkinson's disease


Parkinson disease (PD) is a disabling, progressive condition induced symptoms of olfactory deficit, sleep problems such as rapid eye movement behaviour disorder, constipation and the more recently described male erectile dysfunction(456), due to the interruption of frontal-subcortical loops facilitated cognition and parallel the motor loop(457).
Contrary to common perception, many non-motor symptoms (NMS) also link to early onset of PD(459) and some may even predate the diagnosis of PD based on motor signs(458).


Treatments are depending to the degree of functional and cognitive impairment, according to the suggestion of the Movement Disorder Society (MDS) Task Force on Evidence-Based Medicine (EBM)(480) and Report of the Quality Standards Subcommittee of the American Academy of Neurology(488)
1. Treatments for the non-motor symptoms of Parkinson's disease
a. Tricyclic antidepressants nortriptyline(459) and desipramine(460) for the treatment of depression or depressive symptoms
b. Macrogol for the treatment of constipation(461)
c. Methylphenidate(462) and modafinil(463) for the treatment of fatigue
d. Amantadine for the treatment of pathological gambling(464)(465)
e. Donepezil(466)(467), galantamine(468), and memantine(470) for the treatment of dementia
f. Quetiapine(471)(472) for the treatment of psychosis
g. Fludrocortisone(473)(474) and domperidone(475)(476) for the treatment of orthostatic hypotension
h. Sildenafil(477)(478) for the treatment of erectile dysfunction
i. Ipratropium bromide spray(479)for the treatment of sialorrhea
j. Levodopa/carbidopa controlled release (CR)(481), pergolide(482), eszopiclone(483)(484), melatonin(485) 3 to 5 mg and melatonin 50 mg for the treatment of insomnia
k. Modafinil(486)(487) for the treatment of excessive daytime sleepiness


(457) Frontal-subcortical circuitry and behavior by Bonelli RM1, Cummings JL.(PubMed)
(458) Non-motor symptoms of Parkinson's disease: diagnosis and management by Salawu FK1, Danburam A, Olokoba AB.(PubMed)
(459) Early Parkinson's disease and non-motor issues by Chaudhuri KR1, Naidu Y.(PubMed)
(460) Comparison of desipramine and cognitive/behavioral therapy in the treatment of elderly outpatients with mild-to-moderate depression by Thompson LW1, Coon DW, Gallagher-Thompson D, Sommer BR, Koin D.(PubMed)
(461) Efficacy and complications of polyethylene glycols for treatment of constipation in children: a meta-analysis by Chen SL1, Cai SR, Deng L, Zhang XH, Luo TD, Peng JJ, Xu JB, Li WF, Chen CQ, Ma JP, He YL.(PubMed)
(462) Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial by Kerr CW1, Drake J, Milch RA, Brazeau DA, Skretny JA, Brazeau GA, Donnelly JP.(PubMed)
(463) Pathological gambling in Parkinson disease is reduced by amantadine by Thomas A1, Bonanni L, Gambi F, Di Iorio A, Onofrj M.(PubMed)
(464) Amantadine in the treatment of pathological gambling: a case report by Pettorruso M1, Martinotti G, Di Nicola M, Onofrj M, Di Giannantonio M, Conte G, Janiri L.(PubMed)
(465) Pathological gambling in Parkinson disease is reduced by amantadine by Thomas A1, Bonanni L, Gambi F, Di Iorio A, Onofrj M.(PubMed)
(466) Long-term efficacy of donepezil for relapse of visual hallucinations in patients with dementia with Lewy bodies. by Ukai K1, Fujishiro H, Iritani S, Ozaki N.(PubMed)
(467) Donepezil for dementia due to Alzheimer's disease by Birks J1, Harvey RJ.(PubMed)
(468) The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial by7 Prins ND1, van der Flier WA1, Knol DL2, Fox NC3, Brashear HR4, Nye JS5, Barkhof F6, Scheltens P7.(PubMed)
(469) Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial by Freund-Levi Y1, Jedenius E2, Tysen-Bäckström AC3, Lärksäter M3, Wahlund LO4, Eriksdotter M4.(PubMed)
(470) Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study by Stubendorff K1, Larsson V2, Ballard C3, Minthon L2, Aarsland D4, Londos E2.(PubMed)
(471) Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis by Pérez-Iglesias R1, Ortiz-Garcia de la Foz V2, Martínez García O2, Amado JA3, Garcia-Unzueta MT4, Ayesa-Arriola R2, Suarez-Pinilla P5, Tabares-Seisdedos R6,Crespo-Facorro B2.(PubMed)
(472) Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison by McEvoy JP1, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD.(PubMed)
(473) Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease by Schoffer KL1, Henderson RD, O'Maley K, O'Sullivan JD.(PubMed)
(474) [Reflex syncope and syncope secondary to orthostatic hypotension].[Article in German] by Simonis G1, Gerk U, Pabst F, Machetanz J, Spitzer SG, Schellong S.(PubMed)
(475) Domperidone in the management of orthostatic hypotension by Montastruc JL, Chamontin B, Senard JM, Rascol A.(PubMed)
(476) [Arterial hypertension with orthostatic hypotension caused by dysregulation of the baroreflex. Correction with domperidone and verapamil].[Article in French]by Chamontin B, Villeneuve A, Berlan M, Montastruc JL, Salvador M.(PubMed)
(477) Effect of sildenafil on platelet function and platelet cGMP of patients with erectile dysfunction. by Akand M1, Gencer E, Yaman O, Erişgen G, Tekin D, Ozdiler E.(PubMed)
(478) Sublingual sildenafil in the treatment of erectile dysfunction: faster onset of action with less dose. by Deveci S1, Peşkircioğlu L, Aygün C, Tekin MI, Dirim A, Ozkardeş H.(PubMed)
(479) Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease. by Thomsen TR1, Galpern WR, Asante A, Arenovich T, Fox SH.(PubMed)
(480) The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease by Seppi K1, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C.(PubMed)
(481) Sleep disorders in Parkinson's disease by Stocchi F1, Barbato L, Nordera G, Berardelli A, Ruggieri S.(PubMed)
(482) Daytime sleepiness and alertness in patients with Parkinson disease by Stevens S1, Cormella CL, Stepanski EJ.(PubMed)
(483) The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: a double-blind, randomized, placebo-controlled trial by Tek C1, Palmese LB2, Krystal AD3, Srihari VH2, DeGeorge PC4, Reutenauer EL2, Guloksuz S2.(PubMed)
(484) A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia by Ancoli-Israel S1, Krystal AD, McCall WV, Schaefer K, Wilson A, Claus R, Rubens R, Roth T.(PubMed)
(485) Melatonin in elderly patients with insomnia. A systematic review by Olde Rikkert MG1, Rigaud AS.(PubMed)
(486) Modafinil in the treatment of excessive daytime sleepiness by Valentino RM1, Foldvary-Schaefer N.(PubMed)
(487) Modafinil : a review of its use in excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome and shift work sleep disorder by Keating GM1, Raffin MJ.(PubMed)

Sunday, 15 January 2017

The Conventional Dementia Treatment of Wernicke-Korsakoff Syndrome due to long-term alcohol abuse

Kyle J. Norton (Scholar) 
Health article writer and researcher; Over 10.000 articles and research papers have been written and published on line, including world wide health, ezine articles, article base, healthblogs, selfgrowth, best before it's news, the karate GB daily, etc.,.
Named TOP 50 MEDICAL ESSAYS FOR ARTISTS & AUTHORS TO READ by Disilgold.com Named 50 of the best health Tweeters Canada - Huffington Post
Nominated for shorty award over last 4 years
Some articles have been used as references in medical research, such as international journal Pharma and Bio science, ISSN 0975-6299.


                                 Dementia

Dementia is defined as neuro degeneration syndrome among elder, affecting memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgement over 47 millions
of worldwide population, mostly in the West. The evaluation of the syndrome by holistic medicine has been lacking, especially through conventional medicine research and studies.



           Treatment of Wernicke-Korsakoff Syndrome due to long-term alcohol abuse

Wernicke-Korsakoff Syndrome is a type of dementia resulted of long term alcohol abuse causes of irreversible damage of the brain(447) due to thiamine deficiency with high morbidity and mortality(446).
Wernicke-Korsakoff Syndrome (WKS) is not a rare disorder, particularly in individuals who abuse alcohol, but there are insufficient evidence from randomized controlled clinical trials to guide clinicians in the dose, frequency, route or duration of thiamine treatment(450)

1. Initial treatment consists of reversing the thiamine deficiency by giving supplemental thiamine(448) and intravenous (IV) thiamine has little risk(449), Usually, the treatments begin with an initial intravenous or intramuscular dose, then followed by supplemental oral doses(447).

Patients with diabetes are found to associate with 15% high risk of Wernicke-Korsakoff syndrome(451). Treatments of such patients should be taken accounted of glucose intake(453) as the combined diseases may causedisturbances of consciousness, or intoxication(452) with spiking acute serum glucose level(452).
According to State University of New York at Binghamton, treatment of Wernicke-Korsakoff Syndrome has shown to cause long-term alterations in neurogenesis(reduction of newly neuron generation) and gliogenesis(generation of non-neuronal Glial cells populations)(454).

Thiamine treatment usually can not reverse the loss of memory and intellect of Korsakoff psychosism but stopping alcohol use can prevent additional loss of brain function and damage to the nerves(456).

2. Side effects are not limit to(455)
a. Alcohol withdrawal symptoms
b. Experience hallucinations,
c. Confusion, and/or
d. Agitation.
e. Etc.

Chinese Food Therapy
The Best Way to prevent, treat your disease, including dementia 
and restore your health naturally with Chinese diet

Ovarian Cysts And PCOS Elimination
Holistic System In Existence That Will Show You How ToPermanently Eliminate All Types of Ovarian Cysts Within 2 Months

Super foods Library, Eat Yourself Healthy With The Best of the Best Nature Has to Offer

Pregnancy Miracle
Reverse Infertility And Get Pregnant Naturally
Using Holistic Ancient Chinese Medicine


References
(446) [Diagnostics and treatment of Wernicke-Korsakoff syndrome patients with an alcohol abuse].[Article in Danish] by Nilsson M1, Sonne C.(PubMed)
(447) Complete recovery from undertreated Wernicke-Korsakoff syndrome following aggressive thiamine treatment by Paparrigopoulos T1, Tzavellas E, Karaiskos D, Kouzoupis A, Liappas I(PubMed).
(448) Thiamine in the treatment of Wernicke encephalopathy in patients with alcohol use disorders. by Latt N1, Dore G.(PubMed)
(449) Wernicke-Korsakoff-syndrome: under-recognized and under-treated by Isenberg-Grzeda E1, Kutner HE, Nicolson SE.(PubMed)
(450) Thiamine for Wernicke-Korsakoff Syndrome in people at risk from alcohol abuse by Day E1, Bentham P, Callaghan R, Kuruvilla T, George S.(PubMed)
(451) Evolution of Wernicke-Korsakoff syndrome in self-neglecting alcoholics: preliminary results of relation with Wernicke-delirium and diabetes mellitus by Wijnia JW1, van de Wetering BJ, Zwart E, Nieuwenhuis KG, Goossensen MA.(PubMed)
(452) [Diabetic coma and Wernicke-Korsakoff syndrome. On the clinical significance of acquired thiamine deficiency].[Article in German]by Vieregge P, Stuhlmann W.(PubMed)
(453) Korsakoff's psychosis due to massive beer intake provoked by diabetes insipidus by Farr RW1, Blankenship DC, Viti A, Albrink MJ.(PubMed)
(454) Stage-dependent alterations of progenitor cell proliferation and neurogenesis in an animal model of Wernicke-Korsakoff syndrome by Vetreno RP1, Klintsova A, Savage LM.(PubMed)
(455) Wernicke-Korsakoff Syndrome(Healthline)
(456) Parkinson’s Disease and Parkinson’s Dementia(Healthguide.org)

Saturday, 14 January 2017

The Conventional Treatments of mild and moderate Alzheimer's disease and Diminished quality of acetylcholine - Anticonvulsants

Kyle J. Norton (Scholar) 
Health article writer and researcher; Over 10.000 articles and research papers have been written and published on line, including world wide health, ezine articles, article base, healthblogs, selfgrowth, best before it's news, the karate GB daily, etc.,.
Named TOP 50 MEDICAL ESSAYS FOR ARTISTS & AUTHORS TO READ by Disilgold.com Named 50 of the best health Tweeters Canada - Huffington Post
Nominated for shorty award over last 4 years
Some articles have been used as references in medical research, such as international journal Pharma and Bio science, ISSN 0975-6299.


                                 Dementia

Dementia is defined as neuro degeneration syndrome among elder, affecting memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgement over 47 millions
of worldwide population, mostly in the West. The evaluation of the syndrome by holistic medicine has been lacking, especially through conventional medicine research and studies.



                Treatment of Alzheimer's disease and Diminished quality of acetylcholine

Depending to the causes of disease, most medication are to control the symptoms

3.1. Anticonvulsants
a. Anticonvulsants are a diverse group of pharmaceuticals used in the treatment of seizures(425), chronic neuropathic pain(426), and the clinical syndrome of Alzheimer's disease(427) by suppressing the rapid and excessive firing of neurons(428). Some researchers suggested that seizure pathophysiology may relate to increased amyloid beta-peptide production(429), causing cytoskeletal dysfunction, cerebrovascular changes, neurotransmitter dysfunction or combinations(430). By modification of these pathophysiological pathways, anti-epileptic drugs such as sodium valproate and lacosamide may be useful in the treatment of Alzheimer's disease(431)

b. Side effects are not limit to(432)(433)
b.1. Dizziness
b.2. Drowsiness
b.3. Unsteadiness
b.4. Nausea
b.5. Vomiting
b.6. Skin rashes
b.7. Etc.
Chinese Food Therapy
The Best Way to prevent, treat your disease, including dementia 
and restore your health naturally with Chinese diet

Ovarian Cysts And PCOS Elimination
Holistic System In Existence That Will Show You How ToPermanently Eliminate All Types of Ovarian Cysts Within 2 Months

Super foods Library, Eat Yourself Healthy With The Best of the Best Nature Has to Offer

Pregnancy Miracle
Reverse Infertility And Get Pregnant Naturally
Using Holistic Ancient Chinese Medicine


References
(425) Use of anticonvulsants as prophylaxis for seizures in patients on clozapine by Caetano D1.(PubMed)
(426) Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society by Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, Furlan A, Gilron I, Gordon A, Morley-Forster PK, Sessle BJ, Squire P, Stinson J, Taenzer P, Velly A, Ware MA, Weinberg EL, Williamson OD; Canadian Pain Society.(PubMed)
(427) Management of behavioral problems in Alzheimer's disease. BY Gauthier S1, Cummings J, Ballard C, Brodaty H, Grossberg G, Robert P, Lyketsos C.(PubMed)
(428) Synthesis, neuronal activity and mechanisms of action of halogenated enaminones by Edafiogho IO1, Qaddoumi MG2, Ananthalakshmi KV3, Phillips OA4, Kombian SB5.(PubMed)
(429) Postnatal disruption of the disintegrin/metalloproteinase ADAM10 in brain causes epileptic seizures, learning deficits, altered spine morphology, and defective synaptic functions by Prox J1, Bernreuther C, Altmeppen H, Grendel J, Glatzel M, D'Hooge R, Stroobants S, Ahmed T, Balschun D, Willem M, Lammich S, Isbrandt D, Schweizer M,Horré K, De Strooper B, Saftig P.(PubMed)
(430) Neurotoxicity of Amyloid β-Protein: Synaptic and Network Dysfunction(PMC)
(431) Epileptic seizures in AD patients. by Larner AJ1.(PubMed)
(432) Anticonvulsant Medication for Bipolar Disorder(WebMD)
(433) Anticonvulsant(Wikipedia)